YMAB · Categories · Form 4

YMAB - SEC Form 4 insider transactions

Y-mAbs Therapeutics Inc. (YMAB) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for YMAB

• 258d
  Director Hamill Laura returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  Director Wg Biotech Aps closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  Director Gill David N returned $50,095 worth of shares to the company (30,905 units at $1.62), closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  Director Tyagi Ashu returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  CHIEF BUSINESS OFFICER Gad Thomas returned 60,235 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  EVP, CFO and Treasurer Pfreundschuh Peter P. returned 77,800 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  PRESIDENT & CEO Rossi Michael J returned 129,101 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  SVP & CHIEF OPERATING OFFICER Wilms Joris returned 39,301 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  Director Wedell-Wedellsborg Johan returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  SVP, General Counsel & Secry Larocca John returned 21,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 258d
  Director Healy James returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 336d
  Director Tyagi Ashu was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 336d
  Director Hamill Laura was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 336d
  Director Healy James was granted 25,080 shares, increasing direct ownership by 79% to 56,683 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 336d
  Director Wedell-Wedellsborg Johan was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 336d
  Director Gill David N was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 363d
  CHIEF BUSINESS OFFICER Gad Thomas exercised 103,000 shares at a strike of $2.00, increasing direct ownership by 51% to 305,721 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 449d
  PRESIDENT & CEO Rossi Michael J sold $20,368 worth of shares (3,917 units at $5.20), decreasing direct ownership by 3% to 137,083 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 449d
  CHIEF BUSINESS OFFICER Gad Thomas sold $56,536 worth of shares (10,810 units at $5.23), decreasing direct ownership by 5% to 202,721 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 497d
  CFO and Treasurer Pfreundschuh Peter P. was granted 31,800 shares, increasing direct ownership by 69% to 77,800 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 497d
  CHIEF BUSINESS OFFICER Gad Thomas was granted 32,000 shares, increasing direct ownership by 18% to 213,531 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 497d
  SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 497d
  SVP & CHIEF OPERATING OFFICER Wilms Joris was granted 21,500 shares, increasing direct ownership by 70% to 52,100 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 497d
  PRESIDENT & CEO Rossi Michael J was granted 105,300 shares, increasing direct ownership by 295% to 141,000 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 497d
  SVP, General Counsel & Secry Larocca John was granted 21,500 shares (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 621d
  CHIEF BUSINESS OFFICER Gad Thomas exercised 22,831 shares at a strike of $4.38, increasing direct ownership by 14% to 181,531 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 624d
  CHIEF BUSINESS OFFICER Gad Thomas sold $1,264,650 worth of shares (95,000 units at $13.31) (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 642d
  SVP & CHIEF TECHNICAL OFFICER Lund-Hansen Torben exercised 50,000 shares at a strike of $4.38 and sold $768,500 worth of shares (50,000 units at $15.37) (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 645d
  SVP & CHIEF OPERATING OFFICER Wilms Joris sold $73,450 worth of shares (5,000 units at $14.69), decreasing direct ownership by 14% to 30,600 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 691d
  CFO and Treasurer Pfreundschuh Peter P. was granted 46,000 shares (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 720d
  Director Tagliaferri Mary was granted 3,495 shares, increasing direct ownership by 75% to 8,155 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 720d
  Director Hamill Laura was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 720d
  Director Wedell-Wedellsborg Johan was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 720d
  Director Healy James was granted 3,495 shares, increasing direct ownership by 12% to 31,603 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 720d
  Director Gill David N was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 720d
  Director Tyagi Ashu was granted 3,495 shares, increasing direct ownership by 150% to 5,825 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 722d
  Director Ber Gerard sold $8,664 worth of shares (722 units at $12.00), decreasing direct ownership by 31% to 1,608 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 722d
  CHIEF BUSINESS OFFICER Gad Thomas sold $841,050 worth of shares (70,000 units at $12.02) (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 733d
  Kruse Bo sold $723,055 worth of shares (60,000 units at $12.05) and exercised 60,000 shares at a strike of $2.00 (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 741d
  Gad Thomas sold $395,563 worth of shares (32,351 units at $12.23) (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 811d
  Tagliaferri Mary was granted 4,660 shares (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 818d
  Rajah Vignesh sold $28,283 worth of shares (1,711 units at $16.53), decreasing direct ownership by 5% to 33,889 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 818d
  Gad Thomas sold $64,116 worth of shares (3,900 units at $16.44), decreasing direct ownership by 2% to 158,700 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 818d
  Smith Susan Laura sold $27,837 worth of shares (1,682 units at $16.55), decreasing direct ownership by 5% to 33,918 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 840d
  Rossi Michael J was granted 35,700 shares (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 863d
  Rajah Vignesh was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 863d
  Smith Susan Laura was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 863d
  Lisby Steen was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 863d
  Wilms Joris was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 863d
  Lund-Hansen Torben was granted 17,800 shares, increasing direct ownership by 100% to 35,600 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 863d
  Gad Thomas was granted 22,100 shares, increasing direct ownership by 16% to 162,600 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 863d
  Kruse Bo was granted 18,100 shares, increasing direct ownership by 9% to 210,877 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 890d
  Gad Thomas exercised 50,000 shares at a strike of $2.00, increasing direct ownership by 55% to 140,500 units (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 901d
  Gad Thomas sold $1,001,000 worth of shares (150,000 units at $6.67) (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 924d
  Gad Thomas sold $795,382 worth of shares (150,000 units at $5.30) (SEC Form 4)

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 938d
  SEC Form 4 filed by Gad Thomas

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 938d
  SEC Form 4 filed by Rossi Michael J

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 1090d
  SEC Form 4 filed by Hamill Laura

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
• 1090d
  SEC Form 4 filed by Wedell-Wedellsborg Johan

  4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

Other YMAB categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends